Meridian Bioscience, Inc. reported unaudited earnings results for the first quarter fiscal 2018. For the quarter the company reported adjusted earnings per share of $0.15, which is unchanged from the same period last year, and a penny higher than the Capital IQ consensus forecast of $0.14. Net revenue for the quarter was $52.3 million, up from $46.8 million in the year-ago period, and ahead of the analyst forecast of $49 million. Net earnings was $6.302 million as compared to $6.279 million a year ago. Operating income was $8.061 million as compared to $10.085 million a year ago. Adjusted net earnings was $6.541 million as compared to $6.279 million a year ago. Adjusted basic and diluted EPS was $0.15 same as a year ago.

The company reaffirmed its fiscal 2018 guidance of per share diluted earnings between $0.59 and $0.62 on a GAAP basis and $0.65 and $0.68 on a non-GAAP basis, on net revenues of $207 million to $212 million, before the impact of the tax reform act.